Every peptide protocol should start with a baseline lab panel. This guide explains which biomarkers matter, what the numbers mean, and how to use them to build a protocol that fits your actual biology.
Most platforms ask what your goal is. We start where the science starts, with what your body is actually doing right now.
Without baseline labs, you have no objective way to know whether a protocol is working, what's changing, or whether something is moving in the wrong direction. Your baseline is the starting line.
Certain biomarker patterns, elevated IGF-1, suppressed cortisol, metabolic dysfunction, can make specific peptides inappropriate or outright risky. Labs reveal what the mirror doesn't.
Repeat labs at 8-12 week intervals during any protocol. Changes in IGF-1, inflammation markers, or hormonal markers give you objective data to guide adjustments, not guesswork.
Click any marker to expand the full guide, what it measures, what ranges to target, and which peptide categories it informs.
IGF-1 is the primary monitoring marker for anyone using GH secretagogues, including Ipamorelin, CJC-1295, Sermorelin, and Epithalon. Research suggests that elevated IGF-1 may be associated with increased cancer proliferation risk, making baseline testing before and monitoring during these protocols essential. Conversely, low IGF-1 may help justify GH-stimulating protocols.
GH secretagogues like Ipamorelin, CJC-1295, and Sermorelin can indirectly influence testosterone levels by improving the hormonal milieu. Knowing your baseline testosterone helps differentiate whether symptoms (low libido, poor recovery, fatigue) stem from GH deficiency or androgen deficiency, which points to very different protocols.
GH secretagogues, particularly GHRP-class compounds - can stimulate cortisol release as a side effect. Ipamorelin is generally considered to have minimal cortisol stimulation compared to other GHRPs, but cortisol remains critical context. High baseline cortisol is often associated with poor recovery, disrupted sleep, and immune suppression. Low cortisol may indicate adrenal insufficiency, a scenario requiring medical evaluation before any peptide protocol.
Elevated hsCRP helps justify anti-inflammatory peptide research, particularly BPC-157, TB-500, and Thymosin Alpha-1. It also provides context for metabolic peptides, research suggests that chronic low-grade inflammation directly impairs GH secretion and insulin sensitivity, making it a key variable in interpreting other markers. High hsCRP may also indicate infections, gut permeability, or autoimmune activity worth addressing before layering in peptides.
GH secretagogues, including Ipamorelin and CJC-1295 - can transiently impair insulin sensitivity. For anyone with pre-existing insulin resistance or metabolic syndrome, this is a critical safety consideration. Conversely, GLP-1 receptor agonists like Semaglutide and Tirzepatide are specifically studied to improve insulin sensitivity, making fasting insulin essential baseline context for metabolic peptide protocols.
Vitamin D deficiency is extraordinarily common and is associated with impaired immune function, reduced testosterone production, poor sleep quality, and elevated inflammatory markers, all of which directly affect the context in which peptides operate. Research suggests that inadequate vitamin D may blunt the effectiveness of immune-modulating peptides like Thymosin Alpha-1 and impair GH axis signaling. It's foundational, not optional.
Thyroid dysfunction profoundly affects how other systems respond to peptide protocols. Hypothyroidism suppresses IGF-1 production, impairs GH response, and is a major driver of fatigue, weight gain, and brain fog, symptoms that may be incorrectly attributed to GH deficiency. GH secretagogues like Sermorelin and CJC-1295 will underperform in a hypothyroid state. Screening TSH before GH protocols is essential to avoid chasing the wrong root cause.
HbA1c is mandatory before starting GLP-1 receptor agonists like Semaglutide or Tirzepatide - it establishes baseline glycemic control and helps determine appropriateness. GH secretagogues can also impair glucose metabolism transiently, making HbA1c valuable context for those protocols too. An elevated HbA1c in the pre-diabetes range is often a sign of underlying insulin resistance that should be evaluated in full before building any peptide protocol.
Not sure where to start? Here are three panel tiers based on where you are in your research journey.
Several options exist depending on your insurance coverage, location, and how much detail you want.
Most basic panels are covered by insurance. Ask specifically for the Tier 1 markers, many are standard annual bloodwork. Limitation: physicians may not order optimization-range labs without clinical indication.
Services like Ulta Lab Tests, Walk-In Lab, and LabCorp's direct service allow ordering without a doctor. No insurance, you pay out of pocket. Cost-effective for comprehensive panels, typically $100-400 for full Tier 2.
Clinics like Marek Health, Function Health, and Precision Health specialize in comprehensive panels with clinical interpretation. Best option if you plan to actually use findings to build a supervised protocol.
Always work with a licensed clinician to interpret your results and determine appropriateness of any peptide protocol. Lab values provide context, a qualified clinician provides the clinical judgment. This guide is for educational purposes only.